Cost-utility and budget impact analyses of gefitinib in second-line treatment for advanced non-small cell lung cancer from Thai payer perspective
Aim: To evaluate the cost utility and budget impact of second-line gefitinib for non-small cell lung cancer from a Thai payer perspective. Methods: A Markov model with three health states (pre-progression, post-progression and death) was constructed to estimate direct medical costs and outcomes comp...
Saved in:
Main Authors: | Thongprasert,S., Tinmanee,S., Permsuwan,U. |
---|---|
Format: | Article |
Published: |
Wiley-Blackwell
2015
|
Subjects: | |
Online Access: | http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84857528545&origin=inward http://cmuir.cmu.ac.th/handle/6653943832/38524 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Chiang Mai University |
Similar Items
-
Cost-utility and budget impact analyses of gefitinib in second-line treatment for advanced non-small cell lung cancer from Thai payer perspective
by: Thongprasert S., et al.
Published: (2014) -
Crizotinib treatment for advanced non-small-cell lung cancer patients: a budget impact analysis based in Thailand
by: Thongprasert S., et al.
Published: (2017) -
Docetaxel as second-line chemotherapy for advanced non-small cell lung cancer
by: Thongprasert S., et al.
Published: (2014) -
Crizotinib treatment for advanced non-small-cell lung cancer patients: a budget impact analysis based in Thailand
by: Sumitra Thongprasert, et al.
Published: (2018) -
Crizotinib treatment for advanced non-small-cell lung cancer patients: a budget impact analysis based in Thailand
by: Sumitra Thongprasert, et al.
Published: (2018)